Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK1R+ mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- BioCardia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intracardiac
01
Overview
**NK1R+ mesenchymal stem cells** are allogeneic, culture-expanded, bone marrow-derived mesenchymal stem cells expressing the **Neurokinin-1 receptor (NK1R)**. Substance P is the primary endogenous ligand for NK1R, and this interaction is a key mediator of inflammation in organs such as the heart and lungs. NK1R+ MSC therapy is being developed for cardiovascular and pulmonary indications, including **ischemic heart failure** and **acute respiratory distress syndrome (ARDS) following Covid-19**, where anti-inflammatory and regenerative properties may provide therapeutic benefit. These cells may be delivered intravenously or directly to the heart and are manufactured from pre-screened younger donors by BioCardia. The mechanism of action centers on engagement of Substance P with NK1R on MSCs, offering effects on proliferation, differentiation, migration, and local anti-inflammatory activities[2][4][3].
- Brand names
- CardiALLO NK1R+ MSC
- Other names
- Neurokinin-1 receptor-positive mesenchymal stem cellsNeurokinin1 receptor-positive mesenchymal stem cellsNeurokinin 1 receptor-positive mesenchymal stem cellsNK1R+ MSCsNeurokinin 1 receptor+ MSCs
Beyond the preview
Go deeper on NK1R+ mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK1R+ mesenchymal stem cells.